Cargando…

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib

AIM: We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. PATIENTS AND METHODS: Data from the medical charts of mRCC patients from 8 centers in Greece and Spain we...

Descripción completa

Detalles Bibliográficos
Autores principales: Koutsoukos, Konstantinos, Bamias, Aristotelis, Tzannis, Kimon, Espinosa Montaño, Marta, Bozionelou, Vasiliki, Christodoulou, Christos, Stefanou, Dimitra, Kalofonos, Haralabos, Duran, Ignacio, Papazisis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640393/
https://www.ncbi.nlm.nih.gov/pubmed/29062235
http://dx.doi.org/10.2147/OTT.S141260
_version_ 1783271035628421120
author Koutsoukos, Konstantinos
Bamias, Aristotelis
Tzannis, Kimon
Espinosa Montaño, Marta
Bozionelou, Vasiliki
Christodoulou, Christos
Stefanou, Dimitra
Kalofonos, Haralabos
Duran, Ignacio
Papazisis, Konstantinos
author_facet Koutsoukos, Konstantinos
Bamias, Aristotelis
Tzannis, Kimon
Espinosa Montaño, Marta
Bozionelou, Vasiliki
Christodoulou, Christos
Stefanou, Dimitra
Kalofonos, Haralabos
Duran, Ignacio
Papazisis, Konstantinos
author_sort Koutsoukos, Konstantinos
collection PubMed
description AIM: We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. PATIENTS AND METHODS: Data from the medical charts of mRCC patients from 8 centers in Greece and Spain were reviewed. All patients had received or were continuing to receive second-line everolimus treatment after failure of first-line treatment with pazopanib. No other previous therapies were allowed. The primary end point was the determination of progression-free survival (PFS). RESULTS: In total, 31 patients were enrolled. Of these, 26% had performance status (PS) >0, 88% were of intermediate/poor Memorial Sloan-Kettering Cancer Center (MSKCC) risk group, and only 61% had undergone prior nephrectomy. Median PFS was 3.48 months (95% CI: 2.37–5.06 months). Median overall survival (OS) from everolimus initiation was 8.9 months (95% CI: 6.47–13.14 months). Median OS from pazopanib initiation was 14.78 months (95% CI: 10.54–19.08 months). Furthermore, 32% of patients temporarily discontinued everolimus due to adverse events (AEs), and 22% of patients discontinued everolimus permanently due to toxicity. Most common toxicities were anemia (29%), stomatitis (26%), pneumonitis (19%), and fatigue (10%). Moreover, 14 AEs (27%) were graded as 3 or 4 and were reported by 13 patients (42%). CONCLUSION: This study provides data exclusively on the sequence pazopanib–everolimus in mRCC. Everolimus has a favorable safety profile and is active. The short PFS and OS could be attributed to the fact that the pazopanib–everolimus sequence was mainly offered to patients with adverse prognostic features, resulting in a modest increase in the combined OS of our population.
format Online
Article
Text
id pubmed-5640393
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56403932017-10-23 Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib Koutsoukos, Konstantinos Bamias, Aristotelis Tzannis, Kimon Espinosa Montaño, Marta Bozionelou, Vasiliki Christodoulou, Christos Stefanou, Dimitra Kalofonos, Haralabos Duran, Ignacio Papazisis, Konstantinos Onco Targets Ther Original Research AIM: We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. PATIENTS AND METHODS: Data from the medical charts of mRCC patients from 8 centers in Greece and Spain were reviewed. All patients had received or were continuing to receive second-line everolimus treatment after failure of first-line treatment with pazopanib. No other previous therapies were allowed. The primary end point was the determination of progression-free survival (PFS). RESULTS: In total, 31 patients were enrolled. Of these, 26% had performance status (PS) >0, 88% were of intermediate/poor Memorial Sloan-Kettering Cancer Center (MSKCC) risk group, and only 61% had undergone prior nephrectomy. Median PFS was 3.48 months (95% CI: 2.37–5.06 months). Median overall survival (OS) from everolimus initiation was 8.9 months (95% CI: 6.47–13.14 months). Median OS from pazopanib initiation was 14.78 months (95% CI: 10.54–19.08 months). Furthermore, 32% of patients temporarily discontinued everolimus due to adverse events (AEs), and 22% of patients discontinued everolimus permanently due to toxicity. Most common toxicities were anemia (29%), stomatitis (26%), pneumonitis (19%), and fatigue (10%). Moreover, 14 AEs (27%) were graded as 3 or 4 and were reported by 13 patients (42%). CONCLUSION: This study provides data exclusively on the sequence pazopanib–everolimus in mRCC. Everolimus has a favorable safety profile and is active. The short PFS and OS could be attributed to the fact that the pazopanib–everolimus sequence was mainly offered to patients with adverse prognostic features, resulting in a modest increase in the combined OS of our population. Dove Medical Press 2017-10-06 /pmc/articles/PMC5640393/ /pubmed/29062235 http://dx.doi.org/10.2147/OTT.S141260 Text en © 2017 Koutsoukos et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Koutsoukos, Konstantinos
Bamias, Aristotelis
Tzannis, Kimon
Espinosa Montaño, Marta
Bozionelou, Vasiliki
Christodoulou, Christos
Stefanou, Dimitra
Kalofonos, Haralabos
Duran, Ignacio
Papazisis, Konstantinos
Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
title Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
title_full Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
title_fullStr Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
title_full_unstemmed Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
title_short Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
title_sort real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640393/
https://www.ncbi.nlm.nih.gov/pubmed/29062235
http://dx.doi.org/10.2147/OTT.S141260
work_keys_str_mv AT koutsoukoskonstantinos realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib
AT bamiasaristotelis realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib
AT tzanniskimon realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib
AT espinosamontanomarta realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib
AT bozionelouvasiliki realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib
AT christodoulouchristos realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib
AT stefanoudimitra realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib
AT kalofonosharalabos realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib
AT duranignacio realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib
AT papazisiskonstantinos realworldexperienceofeverolimusassecondlinetreatmentinmetastaticrenalcellcancerafterfailureofpazopanib